Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Microtransplantation + decitabine + cytarabine
- Development stage
- Unknown
- Lead developer
- 307 Hospital of the People's Liberation Army
- Modality
- Small Molecules, Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Microtransplantation + decitabine + cytarabine is a combination chemo-immunotherapy regimen being evaluated for the treatment of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The regimen consists of the hypomethylating agent decitabine and the antimetabolite cytarabine, followed by microtransplantation—the infusion of HLA-mismatched, G-CSF-mobilized donor peripheral blood stem cells (G-PBSC). This approach, developed by the Affiliated Hospital of the Chinese Academy of Military Medical Sciences, is designed to harness a graft-versus-leukemia (GVL) effect from the donor cells and promote rapid hematopoietic recovery after chemotherapy. Unlike conventional allogeneic stem cell transplantation, microtransplantation does not require myeloablative conditioning or post-infusion immunosuppression, significantly reducing the risk of graft-versus-host disease (GVHD) and making it a viable option for older or less fit patients.
- Other names
- MicrotransplantationHLA-mismatched G-PBSC infusionMSTMicro-transplantation
Beyond the preview
Go deeper on Microtransplantation + decitabine + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Microtransplantation + decitabine + cytarabine.